Search

Your search keyword '"Lacouture, Mario E."' showing total 1,153 results
Start Over Author "Lacouture, Mario E."
1,153 results on '"Lacouture, Mario E."'

1. Oral minoxidil for late alopecia in cancer survivors

Author

Kuo, Alyce Mei-Shiuan, Reingold, Rachel E., Ketosugbo, Kwami F., Pan, Alexander, Kraehenbuehl, Lukas, Dusza, Stephen, Gajria, Devika, Lake, Diana E., Bromberg, Jacqueline F., Traina, Tiffany A., Fornier, Monica N., Gucalp, Ayca, D’Alessandro, Brian M., Rotemberg, Veronica, Dauscher, Megan, Shapiro, Jerry, Goldfarb, Shari B., Markova, Alina, and Lacouture, Mario E.

Published
2024
Full Text
View/download PDF

2. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

Author

Gallagher, Emily J., Moore, Heather, Lacouture, Mario E., Dent, Susan F., Farooki, Azeez, Goncalves, Marcus D., Isaacs, Claudine, Johnston, Abigail, Juric, Dejan, Quandt, Zoe, Spring, Laura, Berman, Brian, Decker, Melanie, Hortobagyi, Gabriel N., Kaffenberger, Benjamin H., Kwong, Bernice Y., Pluard, Timothy, Rao, Ruta, Schwartzberg, Lee, and Broder, Michael S.

Published
2024
Full Text
View/download PDF

4. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

Author

Zhao, Jimmy L., Antonarakis, Emmanuel S., Cheng, Heather H., George, Daniel J., Aggarwal, Rahul, Riedel, Elyn, Sumiyoshi, Takayuki, Schonhoft, Joseph D., Anderson, Amanda, Mao, Ninghui, Haywood, Samuel, Decker, Brooke, Curley, Tracy, Abida, Wassim, Feng, Felix Y., Knudsen, Karen, Carver, Brett, Lacouture, Mario E., Wyatt, Alexander W., and Rathkopf, Dana

Published
2024
Full Text
View/download PDF

7. A multidisciplinary approach to optimizing care of patients treated with alpelisib

Author

Rugo, Hope S, Lacouture, Mario E, Goncalves, Marcus D, Masharani, Umesh, Aapro, Matti S, and O'Shaughnessy, Joyce A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Digestive Diseases, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Phosphatidylinositol 3-Kinases, Thiazoles, Alpelisib, Breast cancer, PIK3CA, AE management, Public Health and Health Services, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeThe oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a multidisciplinary approach are needed to provide optimal patient care. The primary objective of this manuscript is to provide comprehensive guidance on minimizing and managing adverse events (AEs) for patients with advanced breast cancer who are receiving alpelisib.MethodsClinical studies, prescribing information, published literature, and relevant guidelines were reviewed to provide recommendations on the prevention and management of alpelisib-associated AEs.ResultsThe most common AEs associated with alpelisib in the phase 3 SOLAR-1 trial were hyperglycemia and rash (which are considered on-target effects of PI3Kα inhibition) and gastrointestinal AEs, including diarrhea, nausea, and decreased appetite. These AEs require regular monitoring, early recognition, and prompt initiation of appropriate treatment. In addition, there are effective strategies to reduce the onset and severity of frequently observed AEs-in particular, onset of hyperglycemia and rash may be reduced by lifestyle changes (such as reduced intake of carbohydrates and regular exercise) and antihistamine prophylaxis, respectively. To reduce risk of severe hyperglycemia, it is essential to achieve adequate glycemic control prior to initiation of alpelisib treatment.ConclusionOverall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.

Published
2022

8. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor TherapyTopical BRAF Inhibitor for Anti-EGFR Toxicities

Author

Lacouture, Mario E, Wainberg, Zev A, Patel, Anisha B, Anadkat, Milan J, Stemmer, Salomon M, Shacham-Shmueli, Einat, Medina, Egmidio, Zelinger, Galit, Shelach, Noa, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Colo-Rectal Cancer, Digestive Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Skin, Adult, Aged, Female, Humans, Male, Middle Aged, Acneiform Eruptions, Administration, Cutaneous, Antineoplastic Agents, Immunological, Cetuximab, Colorectal Neoplasms, Dermatologic Agents, ErbB Receptors, Panitumumab, Proto-Oncogene Proteins B-raf, Treatment Outcome, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts. LUT014 was well tolerated, and there were no dose-limiting toxicities. The acneiform rash improved in the 6 patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation. SIGNIFICANCE: BRAF inhibitor topical therapy could avoid dose reductions of EGFR inhibitors, locally treating the main dose-limiting skin toxicity of this class of agents.This article is highlighted in the In This Issue feature, p. 2113.

Published
2021

9. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features

Author

Ellis, Samantha R, Vierra, Aren T, Millsop, Jillian W, Lacouture, Mario E, and Kiuru, Maija

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Inflammatory and immune system, Acantholysis, Alopecia, Drug Eruptions, Humans, Immune Checkpoint Inhibitors, Keratinocytes, Lichenoid Eruptions, Nevus, Pigmented, Panniculitis, Pemphigoid, Bullous, Pruritus, Psoriasis, Stevens-Johnson Syndrome, Vitiligo, adverse event, atezolizumab, avelumab, bullous pemphigoid, checkpoint inhibitor, CTLA-4, cutaneous, durvalumab, immunotherapy, ipilimumab, lichenoid dermatitis, nivolumab, PD1, PD-L1, pembrolizumab, rash, skin, toxicity, Clinical Sciences, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Antineoplastic agents that use the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T-lymphocyte-associated antigen-4, programmed cell death protein 1, or programmed cell death ligand 1 show improved and sustained responses in patients with cancer. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. As the clinical application of cancer immunotherapies expands, understanding the clinical and histopathologic features of associated cutaneous toxicities becomes increasingly important to dermatologists, oncologists, and pathologists to ensure timely diagnosis and appropriate care. This review discusses cutaneous reactions to immune checkpoint inhibitors, focusing on histopathologic features.

Published
2020

16. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Author

Lacouture, Mario E., primary, Goleva, Elena, additional, Shah, Neil, additional, Rotemberg, Veronica, additional, Kraehenbuehl, Lukas, additional, Ketosugbo, Kwami F., additional, Merghoub, Taha, additional, Maier, Tara, additional, Bang, Alexander, additional, Gu, Stephanie, additional, Salvador, Trina, additional, Moy, Andrea P., additional, Lyubchenko, Taras, additional, Xiao, Olivia, additional, Hall, Clifton F., additional, Berdyshev, Evgeny, additional, Crooks, James, additional, Weight, Ryan, additional, Kern, Jeffrey A., additional, and Leung, Donald Y.M., additional

Published
2024
Full Text
View/download PDF

17. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Author

Friedman, Joshua S., primary, Durham, Benjamin H., additional, Reiner, Anne S., additional, Yabe, Mariko, additional, Petrova‐Drus, Kseniya, additional, Dogan, Ahmet, additional, Pulitzer, Melissa, additional, Busam, Klaus J., additional, Francis, Jasmine H., additional, Rampal, Raajit K., additional, Ulaner, Gary A., additional, Reddy, Ryan, additional, Yeh, Randy, additional, Hatzoglou, Vaios, additional, Lacouture, Mario E., additional, Rotemberg, Veronica, additional, Mazor, Roei D., additional, Hershkovitz‐Rokah, Oshrat, additional, Shpilberg, Ofer, additional, Goyal, Gaurav, additional, Go, Ronald S., additional, Abeykoon, Jithma P., additional, Rech, Karen, additional, Morlote, Diana, additional, Fidai, Shiraz, additional, Gannamani, Vedavyas, additional, Zia, Maryam, additional, Abdel‐Wahab, Omar, additional, Panageas, Katherine S., additional, Rosenblum, Marc K., additional, and Diamond, Eli L., additional

Published
2024
Full Text
View/download PDF

18. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Author

Chen, Steven T, primary, Semenov, Yevgeniy R, additional, Alloo, Allireza, additional, Bach, Daniel Q, additional, Betof Warner, Allison, additional, Bougrine, Amina, additional, Burton, Leeann, additional, Cappelli, Laura C, additional, Castells, Mariana, additional, Cohen, Justine, additional, Dewan, Anna K, additional, Fadden, Riley, additional, Guggina, Lauren, additional, Hegde, Aparna, additional, Huang, Victor, additional, Johnson, Douglas B, additional, Kaffenberger, Benjamin, additional, Kroshinsky, Daniela, additional, Kwatra, Shawn, additional, Kwong, Bernice, additional, Lacouture, Mario E, additional, Larocca, Cecilia, additional, Leventhal, Jonathan, additional, Markova, Alina, additional, McDunn, Jon, additional, Mooradian, Meghan J, additional, Naidoo, Jarushka, additional, Choi, Jennifer, additional, Nambudiri, Vinod, additional, Nelson, Caroline A, additional, Patel, Anisha B, additional, Pimkina, Julia, additional, Rine, Johnathan, additional, Rubin, Krista M, additional, Sauder, Maxwell, additional, Shaigany, Sheila, additional, Shariff, Afreen, additional, Sullivan, Ryan J, additional, Zubiri, Leyre, additional, Reynolds, Kerry L, additional, and LeBoeuf, Nicole R, additional

Published
2024
Full Text
View/download PDF

19. Dermatological Complications of Systemic Therapies for Melanoma

Author

Ramelyte, Egle, Dummer, Reinhard, Libenciuc, Cristina, Phillips, Gregory S., Lacouture, Mario E., Robert, Caroline, Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

25. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Author

Lacouture, Mario E; https://orcid.org/0000-0002-4818-3710, Goleva, Elena; https://orcid.org/0000-0002-4685-9318, Shah, Neil; https://orcid.org/0000-0001-5752-6212, Rotemberg, Veronica; https://orcid.org/0000-0003-0639-2677, Kraehenbuehl, Lukas; https://orcid.org/0000-0001-5411-5661, Ketosugbo, Kwami F; https://orcid.org/0000-0003-1637-1941, Merghoub, Taha; https://orcid.org/0000-0002-1518-5111, Maier, Tara; https://orcid.org/0009-0001-7691-404X, Bang, Alexander; https://orcid.org/0000-0002-1700-2411, Gu, Stephanie; https://orcid.org/0000-0002-6416-785X, Salvador, Trina; https://orcid.org/0009-0009-2346-0660, Moy, Andrea P; https://orcid.org/0000-0001-5431-6682, Lyubchenko, Taras; https://orcid.org/0000-0001-9466-5916, Xiao, Olivia; https://orcid.org/0000-0002-3869-5894, Hall, Clifton F; https://orcid.org/0000-0002-5180-1014, Berdyshev, Evgeny; https://orcid.org/0000-0002-1376-0098, Crooks, James; https://orcid.org/0000-0002-0021-5701, Weight, Ryan; https://orcid.org/0009-0006-0982-2096, Kern, Jeffrey A; https://orcid.org/0000-0001-9709-9622, Leung, Donald Y M; https://orcid.org/0000-0002-0177-3844, Lacouture, Mario E; https://orcid.org/0000-0002-4818-3710, Goleva, Elena; https://orcid.org/0000-0002-4685-9318, Shah, Neil; https://orcid.org/0000-0001-5752-6212, Rotemberg, Veronica; https://orcid.org/0000-0003-0639-2677, Kraehenbuehl, Lukas; https://orcid.org/0000-0001-5411-5661, Ketosugbo, Kwami F; https://orcid.org/0000-0003-1637-1941, Merghoub, Taha; https://orcid.org/0000-0002-1518-5111, Maier, Tara; https://orcid.org/0009-0001-7691-404X, Bang, Alexander; https://orcid.org/0000-0002-1700-2411, Gu, Stephanie; https://orcid.org/0000-0002-6416-785X, Salvador, Trina; https://orcid.org/0009-0009-2346-0660, Moy, Andrea P; https://orcid.org/0000-0001-5431-6682, Lyubchenko, Taras; https://orcid.org/0000-0001-9466-5916, Xiao, Olivia; https://orcid.org/0000-0002-3869-5894, Hall, Clifton F; https://orcid.org/0000-0002-5180-1014, Berdyshev, Evgeny; https://orcid.org/0000-0002-1376-0098, Crooks, James; https://orcid.org/0000-0002-0021-5701, Weight, Ryan; https://orcid.org/0009-0006-0982-2096, Kern, Jeffrey A; https://orcid.org/0000-0001-9709-9622, and Leung, Donald Y M; https://orcid.org/0000-0002-0177-3844

Abstract

Purpose: Immune-related cutaneous adverse events (ircAEs) occur in ≥50% of patients treated with checkpoint inhibitors (CPI), but mechanisms are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted in 200 patients on CPIs (139 with ircAEs, 61 without, control) to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip (STS) extracts and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays. Results: Eight ircAE phenotypes were identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), and bullous dermatitis (4%). All phenotypes showed skin lymphocyte and eosinophil infiltrates. Skin biopsy PCR revealed the highest increase in IFN-gamma mRNA in patients with lichenoid (p<0.0001) and psoriasiform dermatitis (p<0.01) as compared to patients without ircAEs, while the highest IL-13 mRNA levels were detected in the eczema (p<0.0001, compared to control). IL-17A mRNA was selectively increased in psoriasiform (p<0.001), lichenoid (p<0.0001), bullous dermatitis (p<0.05) and MPR (p<0.001), compared to control. Distinct cytokine profiles were confirmed in STS and plasma. Analysis determined increased skin/plasma IL-4 cytokine in pruritus, skin IL-13 in eczema, plasma IL-5 and IL-31 in eczema and urticaria, and mixed-cytokine pathways in MPR. Broad inhibition via corticosteroids or type 2-cytokine targeted inhibition resulted in clinical benefit in these ircAEs. In contrast, significant skin upregulation of type 1/type 17 pathways was found in psoriasiform, lichenoid, bullous dermatitis, and type 1 activation in vitiligo. Conclusions: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.

Published
2024

26. Cutaneous Adverse Events of Systemic Melanoma Treatments

Author

Menzer, Christian, Chen, Steven T., Phillips, Gregory S., Lacouture, Mario E., Flaherty, Keith T., Section editor, Bastian, Boris C., Section editor, Tsao, Hensin, Section editor, Hodi, F. Stephen, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor

Published
2019
Full Text
View/download PDF

28. Dermatologic Cancer Pain Syndromes

Author

Svigos, Katerina, Belum, Viswanath Reddy, Lacouture, Mario E., Gulati, Amitabh, editor, Puttanniah, Vinay, editor, Bruel, Brian M., editor, Rosenberg, William S., editor, and Hung, Joseph C., editor

Published
2019
Full Text
View/download PDF

31. SJS/TEN 2019: From science to translation

Author

Chang, Wan-Chun, Abe, Riichiro, Anderson, Paul, Anderson, Wanpen, Ardern-Jones, Michael R., Beachkofsky, Thomas M., Bellón, Teresa, Biala, Agnieszka K., Bouchard, Charles, Cavalleri, Gianpiero L., Chapman, Nicole, Chodosh, James, Choi, Hyon K., Cibotti, Ricardo R., Divito, Sherrie J., Dewar, Karen, Dehaeck, Ulrike, Etminan, Mahyar, Forbes, Diane, Fuchs, Esther, Goldman, Jennifer L., Holmes, James H., IV, Hope, Elyse A., Hung, Shuen-Iu, Hsieh, Chia-Ling, Iovieno, Alfonso, Jagdeo, Julienne, Kim, Mee Kum, Koelle, David M., Lacouture, Mario E., Le Pallec, Sophie, Lehloenya, Rannakoe J., Lim, Robyn, Lowe, Angie, McCawley, Jean, McCawley, Julie, Micheletti, Robert G., Mockenhaupt, Maja, Niemeyer, Katie, Norcross, Michael A., Oboh, Douglas, Olteanu, Cristina, Pasieka, Helena B., Peter, Jonathan, Pirmohamed, Munir, Rieder, Michael, Saeed, Hajirah N., Shear, Neil H., Shieh, Christine, Straus, Sabine, Sukasem, Chonlaphat, Sung, Cynthia, Trubiano, Jason A., Tsou, Sheng-Ying, Ueta, Mayumi, Volpi, Simona, Wan, Chen, Wang, Hongsheng, Wang, Zhao-Qing, Weintraub, Jessica, Whale, Cindy, Wheatley, Lisa M., Whyte-Croasdaile, Sonia, Williams, Kristina B., Wright, Galen, Yeung, Sonia N., Zhou, Li, Chung, Wen-Hung, Phillips, Elizabeth J., and Carleton, Bruce C.

Published
2020
Full Text
View/download PDF

32. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Author

Markova, Alina, primary, Papadopoulos, Esperanza B., additional, Dusza, Stephen, additional, Rotemberg, Veronica, additional, Ostojic, Jelena, additional, Ai, Rizi, additional, Maier, Tara, additional, Lacouture, Mario E., additional, Tamari, Roni, additional, Gyurkocza, Boglarka, additional, Shaffer, Brian C., additional, Scordo, Michael, additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

36. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Author

Razavi, Pedram, Dickler, Maura N., Shah, Payal D., Toy, Weiyi, Brown, David N., Won, Helen H., Li, Bob T., Shen, Ronglai, Vasan, Neil, Modi, Shanu, Jhaveri, Komal, Caravella, Betty Ann, Patil, Sujata, Selenica, Pier, Zamora, Stephen, Cowan, Aimee M., Comen, Elizabeth, Singh, Andy, Covey, Anne, Berger, Michael F., Hudis, Clifford A., Norton, Larry, Nagy, Rebecca J., Odegaard, Justin I., Lanman, Richard B., Solit, David B., Robson, Mark E., Lacouture, Mario E., Brogi, Edi, Reis-Filho, Jorge S., Moynahan, Mary Ellen, Scaltriti, Maurizio, and Chandarlapaty, Sarat

Published
2020
Full Text
View/download PDF

37. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

Author

Chan, Alexandre, Cameron, Michael C, Garden, Benjamin, Boers-Doets, Christine B, Schindler, Katja, Epstein, Joel B, Choi, Jennifer, Beamer, Laura, Roeland, Eric, Russi, Elvio G, Bensadoun, René-Jean, Teo, Yi Ling, Chan, Raymond J, Shih, Vivianne, Bryce, Jane, Raber-Durlacher, Judith, Gerber, Peter Arne, Freytes, César O, Rapoport, Bernardo, LeBoeuf, Nicole, Sibaud, Vincent, and Lacouture, Mario E

Subjects
Biomedical and Clinical Sciences, Health Services and Systems, Nursing, Health Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Antineoplastic Agents, Humans, Molecular Targeted Therapy, Neoplasms, Patient Outcome Assessment, Quality of Life, Skin Diseases, Surveys and Questionnaires, Targeted cancer therapy, Dermatologic adverse events, Patient-reported outcomes, Health-related quality of life, Medical and Health Sciences, Psychology and Cognitive Sciences, Oncology & Carcinogenesis, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.MethodsA comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.ResultsThirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)).ConclusionsWhile there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.

Published
2015

42. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Author

Bekaii-Saab, Tanios S, Ou, Fang-Shu, Ahn, Daniel H, Boland, Patrick M, Ciombor, Kristen K, Heying, Erica N, Dockter, Travis J, Jacobs, Nisha L, Pasche, Boris C, Cleary, James M, Meyers, Jeffrey P, Desnoyers, Rodwige J, McCune, Jeannine S, Pedersen, Katrina, Barzi, Afsaneh, Chiorean, E Gabriela, Sloan, Jeffrey, Lacouture, Mario E, Lenz, Heinz-Josef, and Grothey, Axel

Published
2019
Full Text
View/download PDF

47. 1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors

Author

Gu, Stephanie, primary, Goleva, Elena, additional, Moy, Andrea P, additional, Ketosugbo, Kwami, additional, Kraehenbuehl, Lukas, additional, Maier, Tara, additional, Salvador, Trina, additional, Shah, Neil J, additional, Weight, Ryan, additional, Rotemberg, Veronica, additional, Kern, Jeffrey A, additional, Leung, Donald Y, additional, and Lacouture, Mario E, additional

Published
2023
Full Text
View/download PDF

49. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Author

Cytryn, Samuel L, primary, Moy, Ryan H, additional, Cowzer, Darren, additional, Shah, Ronak H, additional, Chou, Joanne F, additional, Joshi, Smita S, additional, Ku, Geoffrey Y, additional, Maron, Steven B, additional, Desai, Avni, additional, Yang, Jessica, additional, Sugarman, Ryan, additional, Rao, Devika, additional, Goldberg, Zoe, additional, Charalambous, Carmelina, additional, Lapshina, Maria, additional, Antoine, Ariel, additional, Socolow, Fiona, additional, Trivedi, Nikhil, additional, Capanu, Marinela, additional, Gerdes, Hans, additional, Schattner, Mark A, additional, Simmons, Marc, additional, Lacouture, Mario E, additional, Paroder, Viktoriya, additional, Tang, Laura H, additional, Shia, Jinru, additional, Ilson, David H, additional, Solit, David B, additional, Berger, Michael F, additional, and Janjigian, Yelena Y, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results